SCHEMBL6712019

SCHEMBL6712019

CCOC(=O)CN1C(=O)CCc2cc[c]cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.47
NPSR1 Q6W5P4 1/20 0.47
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
USP2 O75604 1/20 0.44
HTT P42858 1/20 0.44
PIN1 Q13526 1/20 0.44
PIN4 Q9Y237 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
RAB9A P51151 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 2/20 0.41
LOXL2 Q9Y4K0 1/20 0.40
ELANE P08246 1/20 0.40
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6232182 0.90 LMNA (0.47) LMNANPSR1GSK3AGSK3BUSP2
SCHEMBL6720008 0.87 LMNA (0.43) LMNAMEN1KMT2AALDH1A1POLB
SCHEMBL11231189 0.82 NPSR1 (0.61) LMNANPSR1USP2HTTMEN1
SCHEMBL5801112 0.80 MAPT (0.38) LMNARAB9ACYP2C9CYP2C19ALDH1A1
SCHEMBL6233572 0.79 ALDH1A1 (0.38) ALDH1A1POLB
SCHEMBL6234100 0.79 NOTUM (0.40) ALDH1A1GAA
SCHEMBL5800270 0.78 HTT (0.65) NPSR1GSK3AGSK3BUSP2HTT
SCHEMBL10129654 0.78 ATAD2 (0.51) LMNANPSR1GSK3AGSK3BUSP2
SCHEMBL10654062 0.78 LMNA (0.50) LMNANPSR1GSK3AGSK3BUSP2
SCHEMBL10650459 0.78 LMNA (0.68) LMNANPSR1GSK3AGSK3BUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040214832-A1 Piperazine derivative renin inhibitors WARNER-LAMBERT COMPANY LLC 2004-10-28 US claimed
US-20040204455-A1 Piperidine derivative rennin inhibitors WARNER-LAMBERT COMPANY LLC 2004-10-14 US claimed
US-20040214832-A1 Piperazine derivative renin inhibitors WARNER-LAMBERT COMPANY LLC 2004-10-28 US disclosed
US-20040204455-A1 Piperidine derivative rennin inhibitors WARNER-LAMBERT COMPANY LLC 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204455-A1 Piperidine derivative rennin inhibitors REN, ACE, HPN LMNA 1866/4885NPSR1 3127/4885GSK3A 4755/4885
US-20040214832-A1 Piperazine derivative renin inhibitors REN, ACE, AGTR2 LMNA 2783/4885NPSR1 1166/4885GSK3A 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.